Tumor antigens for determining cancer therapy

Patent metadata

Field	Value
Publication number	US-12410221-B2
Application number	US-202318176283-A
Country	US
Kind code	B2
Filing date	Feb 28, 2023
Priority date	Jul 30, 2013
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods for cancer treatment involving a specific set of tumor antigens.

First claim

The invention claimed is:

1. A method for treating triple negative breast cancer in a patient having triple negative breast cancer, the method comprising:
(a) determining an expression pattern of a set of tumor antigens in a sample from the patient having triple negative breast cancer, wherein the set of tumor antigens comprises at least one selected from chromosome X open reading frame 61 (CXorf61), Preferentially expressed Antigen in Melanoma (PRAME), and cancer antigen 1 (CAGE1);
(b) diagnosing the patient having triple negative breast cancer as needing a cancer therapy regimen when at least one tumor antigen selected from CXorf61, PRAME, and CAGE1 is expressed; and
(c) treating the patient having triple negative breast cancer with an immunotherapeutic that targets the at least one tumor antigen expressed in the patient.

2. The method of claim 1 wherein the expression pattern is determined in a sample obtained from a triple negative breast cancer patient.

3. The method of claim 2 wherein the sample comprises cancer cells.

4. The method of claim 1 wherein determining the expression pattern comprises a quantitative and/or qualitative determination of the expression of the tumor antigens.

5. The method of claim 1 wherein determining the expression pattern comprises determining the expression of RNA and/or protein of the tumor antigens.

6. The method of claim 1 wherein the immunotherapeutic provides one or more T cell epitopes of each of the tumor antigens of the set of tumor antigens which are expressed in cancer cells of the patient.

7. The method of claim 6 wherein the immunotherapeutic is an RNA vaccine.

8. A method for preventing or treating triple negative breast cancer in a patient comprising administering to said patient an immunotherapeutic targeting each tumor antigen of a set of tumor antigens, wherein the set of tumor antigens comprises at least one selected from CXorf61, PRAME, and CAGE1.

9. The method of claim 8 which comprises inducing an immune response in the patient against each tumor antigen of the set of tumor antigens.

10. The method of claim 9 wherein the immune response comprises a cellular response.

11. The method of claim 10 wherein the immunotherapeutic is a vaccine and the cellular response is induced by administering the vaccine providing one or more T cell epitopes of each tumor antigen of the set of tumor antigens to the patient.

12. The method of claim 11 wherein the one or more T cell epitopes are comprised in the vaccine in one or more peptides or polypeptides wherein said one or more peptides or polypeptides following administration are processed to produce the one or more T cell epitopes.

13. The method of claim 11 wherein the vaccine is an RNA vaccine.

Assignees

• BioNTech SE
• Tron—Translationale Onkologie An Der Univ Der Johannes Gutenberg—Universitaet Mainz
• Tron—Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz

Inventors

• Sahin Ugur
• Paret Claudia
• Vormbrock Kirsten
• Bender Christian
• Simon Petra
• Hartmann Christoph
• Hubich Stefanie
• Bukur Thomas
• Litzenberger Thorsten

Classifications

• G01N33/57515

  of the breast · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title